Article
Marinus parts with priority review voucher, selling skip-the-line pass to Novo Nordisk for $110M
Rating:
0.0
Views:
87
Likes:
1
Library:
1
Marinus Pharmaceuticals is using a priority review voucher granted four months ago as a financial life preserver, selling the accelerated review pass designated for rare pediatric diseases to Novo | Marinus is selling off a priority review voucher to Novo Nordisk for $110 million. The company plans to use the additional funds to pay for two ongoing phase 3 trials and the launch of its new seizure med, Ztalmy.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value